NKTR News and Press, Nektar Therapeutics From 03/14/22

Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) today announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo (nivolumab) compared to Opdivo ...

Oppenheimer has upgraded Nektar Therapeutics (NASDAQ:NKTR) to outperform from perform given that the stock's current risk/reward ratio is favorable. Shares are 5% higher in premarket trading. The firm also maintained its $21 price target (103% upside based on Tuesday's close). Analy...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Nektar Therapeutics (NKTR) Q4 2021 Earnings Conference Call February 28, 2022 5:00 PM ET Company Participants Jennifer Ruddock – Head-Corporate Affairs Howard Robin – President and Chief Executive Officer Dimitry Nuyten – Chief Medical Officer Jonathan Zalevsky – C...

Nektar Therapeutics press release (NASDAQ:NKTR): Q4 GAAP EPS of -$0.79 beats by $0.02. Revenue of $25M (+6.6% Y/Y) misses by $0.33M. Shares -0.88%. Cash and investments in marketable securities at December 31, 2021 were approximately $0.8 billion as compared to $1.2 billion at&...

Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results PR Newswire SAN FRANCISCO , Feb. 28, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December...

ACAD,ACHC,AGM,AMBA,AMRC,OTCPK:AOIFF,APLS,APPF,APTS,ARCT,ARDX,ASXC,ATRA,AVIR,AY,BANX,BIGC,BLFS,BLNK,BRMK,CAPL,CLDX,CO,CSR,CSTL,DAR,DDD,DNMR,DVAX,ENDP,EVA,FATE,FGEN,FRPT,FSK,GAIA,GDRX,GMRE,GOEV,GPOR,GRPN,HHC,HPQ,HRTX,ICAD,KD,LAZR,LCID,MBI,MDXG,MRTX,NKTR,NMFC,NVAX,NVEE,OCUL,OKE,ONTF,OTIC,PDCE,PG...

FBT is a passive biotechnology ETF, which doesn’t pay any dividend. Baring the past one year, FBT’s price return has outperformed the S&P 500. Effective portfolio rebalancing may determine its future growth. For further details see: FBT: A Long Term Hol...

I will share the 16-year history of the failed efforts to market inhaled insulin for diabetics. I will explain the potential shortcomings of the United-MannKind Partnership. The readers will be exposed to the growing suspicion about the Achilles' Heel that Technosphere is experien...

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial Markets PR Newswire SAN FRANCISCO , Feb. 17, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will a...